Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

PaperCitations, authors & open-access status

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 326 citations, 2024 year and hybrid oa status.

326
Citations
2024
Year
hybrid
OA Status

Related on ScholarIQ

Manabu Morimoto
Author
Naoya Kato
Author
Annals of Oncology
Journal
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Topic
470M+ articles · free account